Global Terbium-152 Market Strategic Research Report

Scope of the Report

In 2025, global production of Terbium-152 was approximately 124 grams, with an average global market price of around $39,000 per gram. Total global production capacity for Terbium-152 reached 220 grams in 2025. The average gross profit margin for the industry stood at 26%. Terbium-152 (Tb-152) is an artificial radioisotope of the rare-earth element terbium, characterized by an atomic number of 65, a mass number of 152, and a half-life of approximately 17.5 hours; it is a nuclide of significant diagnostic value within the terbium radioisotope family. Tb-152 decays into stable Gadolinium-152 (Gd-152) primarily via electron capture and positron emission (β⁺), thereby emitting positron signals suitable for Positron Emission Tomography (PET). Accompanied by gamma-ray emission, it is also applicable to high-resolution molecular imaging research. Because Tb-152 shares the same elemental properties as the therapeutic nuclide Tb-161 and the diagnostic nuclide Tb-155—allowing for labeling with identical chelators and targeting molecules—it is considered a key PET diagnostic nuclide within the "terbium theranostics" framework. It facilitates patient screening prior to Tb-161 therapy, assessment of drug distribution, and precise dosimetry planning. Compared to traditional PET nuclides such as Gallium-68 and Fluorine-18, Tb-152 offers a longer half-life and the unique chemical advantages of the terbium element, making it particularly suitable for studying the *in vivo* behavior of antibodies, long-circulating peptides, and complex targeting molecules.

The upstream sector of the Tb-152 industry chain primarily encompasses high-purity enriched gadolinium targets, accelerator equipment, irradiation target stations, radiochemical separation systems, and nuclide quality analysis platforms. Tb-152 is typically produced via accelerator-based nuclear reactions; common routes include proton bombardment of enriched Gd-152 targets to generate Tb-152, as well as research utilizing targets of other isotopes such as Gd-155 or Gd-156. Another production method involves bombarding heavy-metal targets with high-energy protons and subsequently obtaining high-purity Tb-152 through isotope separation devices. Due to the short half-life of Terbium-152 (Tb-152), production must be tightly coordinated with end-use; consequently, upstream operations typically rely on research cyclotrons, proton accelerators, and large-scale isotope production facilities. Institutions such as CERN-MEDICIS and the Paul Scherrer Institute (PSI) have initiated research into the production of Terbium-series nuclides, driving the development of supply systems for novel theranostic nuclides, including Tb-152. Key upstream technical barriers center on the preparation of enriched Gadolinium (Gd) targets, target recycling, high-purity separation, control of nuclide impurities, and rapid logistics systems for short-lived nuclides. The midstream sector comprises national laboratories, medical isotope R&D institutions, radiopharmaceutical companies, and nuclear medicine technology platforms; these entities are responsible for the separation and purification of Tb-152 from irradiated targets, chemical conversion, and radiopharmaceutical labeling. As Terbium and Gadolinium are both lanthanides with similar chemical properties, Tb-152 production requires highly selective processes—such as ion exchange, extraction chromatography, or multi-column separation—to remove unreacted Gd targets and potential impurity nuclides like Tb-151 and Tb-154. Purified Tb-152 typically exists as a Tb³⁺ solution and is subsequently conjugated with chelating agents (e.g., DOTA or DOTA derivatives) to form radiopharmaceuticals suitable for PET imaging research. Midstream quality control focuses on nuclidic purity, radiochemical purity, specific activity, metal impurity content, labeling stability, and the evaluation of *in vivo* metabolic behavior. With the advancement of precision nuclear medicine, midstream technology is shifting from simple nuclide production toward an integrated service model encompassing nuclide preparation, targeted molecule development, and dosimetry analysis. Downstream applications of Tb-152 primarily involve nuclear medicine centers, oncology diagnostic facilities, radiopharmaceutical R&D companies, and precision medicine research platforms. Its most significant application is as a PET diagnostic nuclide; it forms an elemental theranostic pair with the therapeutic nuclide Tb-161, enabling a "diagnosis-to-therapy" closed loop through the use of identical targeting molecules. For instance, PET imaging using Terbium-152-labeled targeting peptides or small molecules allows for the pre-assessment of tumor target expression, drug distribution, and therapeutic dosages, thereby informing the selection of subsequent treatment regimens—such as those utilizing Terbium-161. This approach minimizes pharmacokinetic disparities between different elemental radionuclides and enhances the precision of personalized radiopharmaceutical therapy. Furthermore, the relatively long half-life of Terbium-152 (approximately 17.5 hours) makes it more suitable than certain short-lived PET radionuclides for inter-regional transport and complex biodistribution studies, particularly those involving antibodies, nanocarriers, and long-circulating drugs. As multi-modal radiotherapies utilizing alpha, beta, and Auger electron emissions continue to evolve, Terbium-152 is poised to become a key diagnostic component within the Terbium radionuclide platform; however, its commercialization remains constrained by factors such as supply scale, production costs, clinical validation, and the regulatory approval process.

The development of precision radiopharmaceuticals and the integration of diagnostics and therapeutics (theranostics) are the primary drivers of the growing demand for Terbium-152. With the rapid advancement of precision tumor diagnostics and radionuclide therapy, the traditional model of using "diagnostic radionuclides" and "therapeutic radionuclides" separately is shifting toward a theranostic pairing approach. As a positron emission tomography (PET) diagnostic radionuclide, Terbium-152 shares the same elemental properties as the therapeutic radionuclide Terbium-161; both can be labeled using identical chelator systems and targeting molecules. This allows data on drug distribution, tumor uptake, and dosimetry obtained during the diagnostic phase to more accurately predict therapeutic outcomes. This "same-element diagnostic-therapeutic closed-loop" model minimizes pharmacokinetic differences between radionuclides and enhances the precision of personalized treatment, thereby garnering sustained attention in the treatment of neuroendocrine tumors, prostate cancer, and other receptor-targeted malignancies.

The platform-based development of terbium radionuclides creates long-term application potential for Terbium-152. In recent years, the field of nuclear medicine has increasingly focused on the value of a multi-radionuclide terbium suite—comprising Terbium-152 (PET diagnostics), Terbium-155 (SPECT diagnostics), Terbium-161 (beta-particle and Auger electron therapy), and Terbium-149 (alpha therapy research)—to form a comprehensive radionuclide system covering diverse diagnostic and therapeutic scenarios. Compared to traditional diagnostic-therapeutic pairs (such as Gallium-68/Lutetium-177), the terbium series offers advantages such as consistent elemental chemistry, unified labeling methods, and predictable pharmacokinetic behavior, promising to reduce technical transition costs during radiopharmaceutical R&D. As the demand for precision medicine and personalized nuclear medicine therapies rises, the importance of Terbium-152 as a PET diagnostic agent will grow, driving the evolution of the terbium radionuclide series from isolated research products into a comprehensive medical technology platform.

Advancements in production technology and supply chain development are critical drivers for the industrialization of Terbium-152. Currently, Terbium-152 is primarily produced using accelerators, utilizing methods such as proton bombardment of enriched gadolinium targets, high-energy proton-induced reactions, and mass separation techniques. Future industry development will focus on enhancing the utilization efficiency of enriched gadolinium targets, optimizing production processes for low-energy cyclotrons, increasing radionuclide purity, and reducing production costs. Furthermore, given that Terbium-152 has a half-life of approximately 17.5 hours—necessitating precise timing coordination across production, purification, transportation, and clinical application—it is essential to establish regional isotope production centers, automated radiochemical preparation platforms, and standardized quality control systems.

This report presents a comprehensive overview of the global Terbium-152 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Radionuclide Purity: <99%
• Radionuclide Purity: ≥99%

Segment by Product Form

• Terbium-152 Radionuclide Stock Solution
• Terbium-152 Labeling Precursor
• Terbium-152 Standard Source
• Terbium-152 Irradiation Target Material

Segment by Production Route

• Production of Enriched Gadolinium-152 Target
• Production of Enriched Gadolinium-155 Target
• Production of Natural Gadolinium Target
• Production via High-energy Proton Spallation

Segment by Quality Grade

• Nuclear Physics Research Grade
• Medical Isotope Research Grade
• Metrological Standard Grade

Segment by Application

• Nuclear Medicine
• Industrial Tracer
• Scientific Research

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Terbium-152 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Nuclear Medicine, Industrial Tracer, Scientific Research evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact